Skip to main content
SpringerLink
Log in

Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters

  • Review
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

This article focuses on recent research on the cytochrome P450 2D (CYP2D) catalyzed synthesis of themonoaminergic neurotransmitters dopamine and serotonin in the brain and on the influence of psychotropic drugs on the activity of brain CYP2D. Recent in vitro and in vivo studies performed in rodents indicate that dopamine and serotonin may be formed in the brain via alternative CYP2D-mediated pathways, i.e., tyramine hydroxylation and 5-methoxytryptamine O-demethylation, respectively. The contribution of these alternative pathways to the total synthesis of brain neurotransmitters may be higher in humans and may be significantly increased under specific conditions, such as tyrosine hydroxylase and amino acid decarboxylase or tryptophan hydroxylase deficiency. These alternative pathways of neurotransmitter synthesismay also becomemore efficient when the CYP2D enzyme ismutated or activated by inducers (e.g., alcohol, nicotine, psychotropics), which may be of importance in some neurodegenerative or psychiatric diseases.

In addition to the previously observed influence of antidepressants and neuroleptics on CYP2D in the liver, the investigated drugs also produce an effect on CYP2D in the brain. However, their effect on brain CYP2D is different than that in the liver and is structure-dependent. The observed psychotropic drug-brain CYP2D interactions may be important for the metabolism of endogenous neuroactive substrates (e.g., monoaminergic neurotransmitters, neurosteroids) and for the local biotransformation of drugs. The results are discussed with regard to the contribution of CYP2D to the total synthesis of neurotransmitters in the brain in vivo as well as the possible significance of these alternative pathways in specific physiological and pathological conditions and in the pharmacological actions of psychotropic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baum LO, Strobel HW: Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones. Brain Res, 1997, 765, 67–73.

    Article  CAS  PubMed  Google Scholar 

  2. Beck O, Jonsson G: In vivo formation of 5-methoxytryptamine from melatonin in rat. J Neurochem, 1981, 36, 2013–2018.

    Article  CAS  PubMed  Google Scholar 

  3. Berry MD: Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem, 2004, 90, 257–271.

    Article  CAS  PubMed  Google Scholar 

  4. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism and personality. Lancet, 1989, 1, 555.

    Article  CAS  PubMed  Google Scholar 

  5. Bromek E, Haduch A, Daniel WA: The ability of cytochrome P450 2D forms to synthesize dopamine in the brain: An in vitro study. Eur J Pharmacol, 2010, 626, 171–178.

    Article  CAS  PubMed  Google Scholar 

  6. Bromek E, Haduch A, Gołembiowska K, Daniel WA: Cytochrome P450-mediates dopamine formation in the brain in vivo. JNeurochem, 2011, 118, 806–815.

    Article  CAS  PubMed  Google Scholar 

  7. Bromek E, Haduch A, Gołembiowska K, Daniel WA: The formation of serotonin from 5-methoxytryptamine via cytochrome P450 in the brain in vivo - a microdialysis study. Eur Neuropsychopharmacol, 2013, 23, Suppl 2, S240–S241.

    Article  Google Scholar 

  8. Chen AR, Irvine RJ, Bochner F, Somogyi AA: Morphine formation from codeine in rat brain: possible mechanism of codeine analgesia. Life Sci, 1990, 46, 1067–1074.

    Article  CAS  PubMed  Google Scholar 

  9. Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale RF, Yu A et al.: Potential role of CYP2D6 in the central nervous system. Xenobiotica, 2013, 43, 973–984.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chow T, Imaoka S, Hiroi T, Funae Y: Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos, 1999, 27, 188–192.

    CAS  PubMed  Google Scholar 

  11. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203–217.

    Article  CAS  PubMed  Google Scholar 

  12. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possibile induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol, 2002, 54, 1545–1552.

    CAS  PubMed  Google Scholar 

  13. Daniel WA, Haduch A, Wójcikowski J: Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo – possible involvement of different mechanisms. Eur Neuropsychopharmacol, 2005, 15, 103–110.

    Article  CAS  PubMed  Google Scholar 

  14. Di Chiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA, 1988, 85, 5274–5278.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ferrari R, Le Novère N, Picciotto MR, Changeux JP, Zoll M: Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci, 2001, 15, 1810–1818.

    Article  Google Scholar 

  16. Funae Y, Kishimoto W, Cho T, Niwa T, Hiroi T: CYP2D in the brain. Drug Metab Pharmacokin, 2003, 18, 337–349.

    Article  CAS  Google Scholar 

  17. Gonzáles I, Peñas-Lledo, EM, Pérez B, Dorado P, Alvarez M, Llerena A: Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics, 2008, 9, 833–840.

    Article  CAS  Google Scholar 

  18. Haduch A, Bromek E, Daniel WA: The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. Eur J Pharmacol, 2011, 651, 51–58.

    Article  CAS  PubMed  Google Scholar 

  19. Haduch A, Bromek E, Sadakierska-Chudy A, Wójcikowski J, Daniel WA: The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study. Pharmacol Res, 2013, 67, 53–59.

    Article  CAS  PubMed  Google Scholar 

  20. Haduch A, Bromek E, Wójcikowski J, Gołembiowska K, Daniel WA: Involvement of cytochrome P450 (CYP) in melatonin-serotonin transformation in the brain. The 11th World Congress of Biological Psychiatry, 23–27 June, Kyoto, Japan, 2013, P–18–013.

  21. Hansson T, von Bahr C, Marklund M, Svensson JO, Ingelman-Sundberg M, Lundström J: Different regiospecificity in the hydroxylation of the antidepressant desmethylimipramine between rat brain and liver. Pharmacol Toxicol, 1992, 71, 416–419.

    Article  CAS  PubMed  Google Scholar 

  22. Hedlund E, Wyss A, Kainu T, Backlund M, Köhler C, Pelto-Huikko M, Gustafsson JÅ, Warner M: Cytochrome P4502D4 in the brain: Specific neuronal regulation by clozapine and toluene. Mol Pharmacol, 1996, 50, 342–350.

    CAS  PubMed  Google Scholar 

  23. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun, 1998, 249, 838–843.

    Article  CAS  PubMed  Google Scholar 

  24. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y: Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology, 2001, 142, 3901–3908.

    Article  CAS  PubMed  Google Scholar 

  25. Kirchheiner J, Seeringer A, Godoy A, Ohmle B, Maier C, Beschoner P, Sim EJ, Viviani R: CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatr, 2011, 16, 333–341.

    Article  CAS  Google Scholar 

  26. Kishimoto W, Hiroi T, Shiraishi M, Osada M, Imaoka S, Kominami S, Igarashi T, Funae Y: Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology, 2004, 145, 699–705.

    Article  CAS  PubMed  Google Scholar 

  27. Mann A, Miksys S, Lee A, Mash DC, Tyndale RF: Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology, 2008, 55, 1147–1155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF: Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem, 2002, 82, 1376–1387.

    Article  CAS  PubMed  Google Scholar 

  29. Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, Tyndale RF: Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica, 2000, 30, 547–564.

    Article  CAS  PubMed  Google Scholar 

  30. Miksys S, Tyndale RF: Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci, 2013, 38, 152–163.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Patel S, Dulluc J, Geffard M: Comparison of serotonin and 5-methoxytryptamine immunoreactivity in rat raphe nuclei. Histochemistry, 1986, 85, 259–263.

    Article  CAS  PubMed  Google Scholar 

  32. Pinna G, Costa E, Guidotti A: Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteriod content at doses that are inactive on 5-HT reuptake. Psychopharmacology, 2006, 186, 362–372.

    Article  CAS  PubMed  Google Scholar 

  33. Schyman P, Usharani D, Wang Y, Shaik S: Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin? J Phys Chem B, 2010, 114, 7078–7089.

    Article  CAS  PubMed  Google Scholar 

  34. Singh S, Singh K, Patel DK, Singh C, Nath C, Singh VK, Singh RK, Singh MP: The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydro-pyridine-induced Parkinson’s disease phenotype and nicotine-mediated neuroprotection. Rejuvenation Res, 2009, 12, 185–197.

    Article  CAS  PubMed  Google Scholar 

  35. Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP: Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med, 2012, 52, 1294–1306.

    Article  CAS  PubMed  Google Scholar 

  36. Strobel HW, Thompson CM, Antonovic L. Cytochromes P450 in brain: function and significance. Curr Drug Me-tab, 2001, 2, 199–214.

    Article  CAS  PubMed  Google Scholar 

  37. Ströhle A, Pasini A, Romeo E, Hermann B, Spalletta G, di Michele F, Holsboer F, Rupprecht R: Fluoxetine decreases concentrations of 3 α, 5 α-tetrahydrodeoxy corticosterone (THDOC) in major depression. J Psychiatr Res, 2000, 34, 183–186.

    Article  PubMed  Google Scholar 

  38. Thompson CM, Capdevila JH, Strobel HW: Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther, 2000, 294, 1120–1130.

    CAS  PubMed  Google Scholar 

  39. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA, 1998, 95, 3239–3244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW et al.: Cytochrome P-450 activities in human and rat brain microsomes. Brain Res, 2000, 855, 235–243.

    Article  CAS  PubMed  Google Scholar 

  41. Warner M, Gustafsson JĹ: Effect of ethanol on cytochrome P450 in the rat brain. Proc Natl Acad Sci USA, 1994, 91, 1019–1023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 2003, 13, 173–181.

    Article  CAS  PubMed  Google Scholar 

  43. Yue J, Miksys S, Hoffmann E, Tyndale RF: Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci, 2008, 33, 54–63.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, Polish Academy of Sciences, Kraków, Smętna 12, PL 31-343, Poland

    Anna Haduch, Ewa Bromek & Władysława A. Daniel

Authors
  1. Anna Haduch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ewa Bromek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Władysława A. Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Władysława A. Daniel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haduch, A., Bromek, E. & Daniel, W.A. Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol. Rep 65, 1519–1528 (2013). https://doi.org/10.1016/S1734-1140(13)71513-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1734-1140(13)71513-5

Key words

Search

Navigation